Responses
Invited Speaker Presentation
S5. Proffered paper: Maintenance therapy of metastatic colorectal carcinoma with the TLR-9 agonist MGN1703: clinical and immunological predictive pretreatment factors of activity in the IMPACT trial
Compose a Response to This Article
Other responses
No responses have been published for this article.